Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

TL-201 VERSUS TECHNETIUM-99M-MIBI SPECT IN EVALUATION OF CHILDHOOD BRAIN-TUMORS - A WITHIN-SUBJECT COMPARISON JOURNAL OF NUCLEAR MEDICINE OTUAMA, L. A., Treves, S. T., LARAR, J. N., Packard, A. B., KWAN, A. J., Barnes, P. D., Scott, R. M., Black, P. M., Madsen, J. R., Goumnerova, L. C., Sallan, S. E., Tarbell, N. J. 1993; 34 (7): 1045-1051

Abstract

We previously found that 201TI SPECT is a highly specific agent for detection of metabolic activity of childhood brain tumors. To compare the relative diagnostic accuracy of 201TI and a technetium-based tumor-avid agent, we have obtained SPECT in 19 children using 201TI (37-111 MBq) followed immediately by 99mTc-methoxyisobutylisonitrile (MIBI) (370-740 MBq) intravenously. Moderate to intense focal uptake of both tracers characterized true positive cases (n = 6). Lesion boundaries were better defined by MIBI. Uptake of MIBI by choroid plexus occurred despite pretreatment with potassium perchlorate (6 mg/kg) and complicated interpretation of deep/paraventricular lesions. Preliminary assessment indicated sensitivity approximately 67% (TI and MIBI); specificity approximately 91% (TI); approximately 100% (MIBI). Two tumors (medulloblastoma, dysgerminoma) were TI/MIBI nonavid. Semi-quantitative assessment of tracer uptake was made using a ratio of radioactivity in tumor-containing areas compared to uninvolved brain. Ratio values were (mean +/- s.d.) 7.88 +/- 7.70 (TI) and 27.1 +/- 36.41 (MIBI). The spectrum of tumor avidity is similar for TI and MIBI. Clearer identification of boundaries by MIBI may be an advantage in applications, e.g., radiotherapy port planning.

View details for Web of Science ID A1993LL23800009

View details for PubMedID 8315477